NCT04850027 is a clinical trial of TME+Lateral lymph node dissection. in Rectal Cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Who is sponsoring NCT04850027?

NCT04850027 is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

What drugs are being tested in NCT04850027?

Interventions in NCT04850027: TME+Lateral lymph node dissection..

What condition does NCT04850027 study?

NCT04850027 studies Rectal Cancer.

Is NCT04850027 still recruiting?

NCT04850027 is currently status unknown. Last updated 26 April 2021.

Last reviewed 2021-04-26 · How we verify

NCT04850027

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MRI-guided Lateral Lymph Node Dissection in Rectal Cancer

Status unknown Last updated 26 April 2021

What this trial tests

trial testing TME+Lateral lymph node dissection. in Rectal Cancer in 268 participants. Status unknown.

Timeline

1 January 2021

Primary endpoint
31 December 2022

31 December 2025

Quick facts

Lead sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	268
Start date	1 January 2021
Primary completion	31 December 2022
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

TME+Lateral lymph node dissection.

Conditions studied

Rectal Cancer — all drugs for Rectal Cancer →

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Who can join

Adults 18 to 75, any sex, with Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the oncological outcome of lateral lymph node dissection in low rectal cancer based on MRI

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Effective dissecting range and prognostic significance of lateral pelvic lymph node dissection for middle-low rectal cancer patients with lateral pelvic lymph node metastasis: Results of a large multicenter lateral node collaborative group in China.
Zhou S, Tang J, Liang J, Lou Z, et al · · 2022 · cited 7× · PMID 36033473 · DOI 10.3389/fonc.2022.916285
Optimization of therapeutic strategies for selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in patients with rectal cancer with clinical suspected lateral lymph node metastasis.
Liu Y, Bao M, Jiang Y, Li F, et al · · 2023 · cited 4× · PMID 37886180 · DOI 10.3389/fonc.2023.1271463
Can neoadjuvant chemoradiotherapy before lateral pelvic lymph node dissection improve local control and prognosis in rectal cancer patients with clinically suspected lateral lymph node metastasis? A multicenter lateral node study in China.
Xie Z, Chen Q, Feng B, Jiang Y, et al · · 2024 · cited 3× · PMID 38263067 · DOI 10.1186/s12885-024-11867-w
The diagnosis and oncological outcomes of obturator and internal iliac lymph node metastasis in middle-low rectal cancer: results of a multicenter Lateral Node Collaborative Group study in China.
Huang F, Wei R, Zhou S, Mei S, et al · · 2024 · cited 2× · PMID 39497010 · DOI 10.1007/s12672-024-01500-4
Oncologic Benefit of Adjuvant Therapy in Lateral Pelvic Lymph Node Metastasis following Neoadjuvant Chemoradiotherapy and Lateral Pelvic Lymph Node Dissection.
Jiang YJ, Zhou SC, Chen JH, Liang JW. · · 2022 · cited 2× · PMID 36313037 · DOI 10.7150/jca.77689
Prognosis of lymph node metastasis confined to lateral pelvic or mesenteric nodes in mid-low rectal cancer: multicentre retrospective cohort study.
Huang F, Xiao T, Zhou S, Zhao F, et al · · 2025 · cited 1× · PMID 40924886 · DOI 10.1093/bjsopen/zraf097
Interpretable Machine Learning Models for Predicting Lateral Pelvic Lymph Node Metastasis in Rectal Cancer: A Chinese Multicenter Retrospective Study.
Xiao T, Zhao W, Sun Z, Wei F, et al · · 2025 · PMID 40961405 · DOI 10.1200/po-25-00192
KLF12 as a potential biomarker for lateral pelvic lymph node metastases in advanced rectal cancer.
Xiao T, Wei F, Zhou S, Zhao F, et al · · 2025 · PMID 40358726 · DOI 10.1007/s00262-025-03991-8

Verify or expand the search:

Other recruiting trials for Rectal Cancer

Currently open trials in the same condition.

NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
NCT07501845 — Registry Maastro Applicator · recruiting
NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting

Other Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

NCT07531563 — Protein Supplementation for Radiation- Induced Oral Mucositis in Head and Neck Cancer Patients Receiving Radiotherapy · NA · not yet recruiting
NCT07537049 — BR101 in Patients With Relapsed/Refractory Multiple Myeloma · Phase 1 · not yet recruiting
NCT07187154 — The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy · NA · not yet recruiting
NCT07530549 — A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Che · Phase 2 · not yet recruiting
NCT07507058 — Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04850027 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Last refreshed: 26 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04850027.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing